Unity Biotechnology
Unity Biotechnology is a startup biotechnology company that develops drugs which target senescent cells.
The company's products in development include UBX0101, targeting knee osteoarthritis, and UBX1967, a preclinical product targeting ophthalmologic diseases. Both are senolytic medicines.
On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million.
